Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL851464 | 0.81 | LAP3 (0.36) | — | |
| SCHEMBL23270909 | 0.72 | CA12 (0.32) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL16589417 | 0.66 | TP53 (0.32) | — | |
| SCHEMBL1647708 | 0.64 | P2RX4 (0.31) | — | |
| SCHEMBL22199559 | 0.64 | TP53 (0.30) | — | |
| SCHEMBL3062829 | 0.64 | CA2 (0.35) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL8530586 | 0.64 | CA2 (0.35) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL898767 | 0.64 | CA2 (0.35) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL24177184 | 0.63 | FDPS (0.34) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL25000746 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468359-B2 | Compositions comprising oxophosphonate-based metalloproteinase inhibitors | YISSUM RESEARCH DEVELPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (US) | 2008-12-23 | — | — | US | disclosed |
| US-20060199787-A1 | COMPOSITIONS COMPRISING OXOPHOSPHONATE-BASED METALLOPROTEINASE INHIBITORS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199787-A1 | COMPOSITIONS COMPRISING OXOPHOSPHONATE-BASED METALLOPROTEINASE INHIBITORS | ENPP1, MMP1, MMP9 | CA12 819/4885CA1 254/4885CA2 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.